Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New HHS office to distribute stimulus funds

Executive Summary

Office of Recovery Act Coordination has been established to oversee HHS' distribution of an estimated $137 billion in funds granted under the American Recovery and Reinvestment Act, agency announces March 11. The office is tasked with distributing the money in a timely, transparent fashion. "We have already worked to put more than $3 billion in Recovery Act funds into states, and the new Office of Recovery Act Coordination will enhance and streamline our efforts," HHS says. Agency veteran Dennis Williams will head the new office as deputy assistant secretary for recovery act coordination. He has worked in HHS' Health Resources Services Administration and in the Office of the Assistant Secretary for Management and Budget. The Recovery Act, signed by President Obama in February, includes $1.1 billion in comparative effectiveness research funding (1"The Pink Sheet," Feb. 23, 2009, p. 5)

You may also be interested in...



Where’s The Comparative Effectiveness Money Going? Plan Is Due July 30

Questions swirling around the $1.1 billion in comparative effectiveness research funding should be answered by July 30. That's when a report is due to Congress outlining details of how the money provided in the economic stimulus package for the research will be spent

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel